Insider Ledger
KALV insider buying and SEC filings, explained
KalVista Pharmaceuticals, Inc. · CIK 1348911
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
- Former names
- Carbylan Therapeutics, Inc.; Carbylan Biosurgery, Inc; Carbylan Biosurgery Inc
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$6.2M
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| May 26, 2026 | Sale | Paul K. Audhya (Chief Medical Officer) sold 2,239 shares at $26.78 ($60K). Holdings down 1% to 150,260 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 27, 2026 |
| May 26, 2026 | Sale | Nicole Sweeny (Chief Commercial Officer) sold 1,489 shares at $26.78 ($40K). Holdings down 2% to 59,291 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 27, 2026 |
| May 26, 2026 | Sale | Christopher Yea (Chief Development Officer) sold 1,966 shares at $26.78 ($53K). Holdings down 1% to 229,918 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 27, 2026 |
| May 22, 2026 | Sale | Paul K. Audhya (Chief Medical Officer) sold 2,685 shares at $26.78 ($72K). Holdings down 2% to 147,499 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 26, 2026 |
| May 22, 2026 | Sale | Nicole Sweeny (Chief Commercial Officer) sold 1,861 shares at $26.78 ($50K). Holdings down 3% to 55,780 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 26, 2026 |
| May 22, 2026 | Sale | Brian Piekos (CFO) sold 1,489 shares at $26.78 ($40K). Holdings down 6% to 21,661 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 26, 2026 |
| May 22, 2026 | Sale | Christopher Yea (Chief Development Officer) sold 2,358 shares at $26.78 ($63K). Holdings down 1% to 228,759 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 26, 2026 |
| May 22, 2026 | Sale | Benjamin L Palleiko (CEO and Director) sold 10,926 shares at $26.78 ($293K). Holdings down 2% to 479,989 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 26, 2026 |
| May 18, 2026 | Sale | Paul K. Audhya (Chief Medical Officer) sold 1,032 shares at $26.76 ($28K). Holdings down 1% to 143,934 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 19, 2026 |
| May 18, 2026 | Sale | Christopher Yea (Chief Development Officer) sold 1,108 shares at $26.76 ($30K). Holdings down <1% to 227,367 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 19, 2026 |
| May 18, 2026 | Sale | Benjamin L Palleiko (CEO and Director) sold 1,129 shares at $26.76 ($30K). Holdings down <1% to 467,665 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 19, 2026 |
| May 12, 2026 | Sale | Benjamin L Palleiko (CEO and Director) sold 3,322 shares at $26.71 ($89K). Holdings down 1% to 466,375 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 13, 2026 |
| Apr 17, 2026 | Sale | Paul K. Audhya (Chief Medical Officer) sold 2,686 shares at $20.22 ($54K). Holdings down 2% to 142,547 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 20, 2026 |
| Apr 17, 2026 | Sale | Nicole Sweeny (Chief Commercial Officer) sold 1,862 shares at $20.22 ($38K). Holdings down 3% to 51,391 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 20, 2026 |
| Apr 17, 2026 | Sale | Brian Piekos (CFO) sold 1,862 shares at $20.22 ($38K). Holdings down 9% to 18,150 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 20, 2026 |
| Apr 17, 2026 | Sale | Benjamin L Palleiko (CEO and Director) sold 9,550 shares at $20.22 ($193K). Holdings down 2% to 462,577 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Apr 20, 2026 |
| Mar 25–26, 2026 | Sale | Bong Y Koh (10% owner) sold 214,631 shares indirectly between Mar 25 and Mar 26 at about $17.20 ($3.7M). Indirect holdings down 4% to 5,089,354 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 6 other reporting owners. | SEC filing Filed Mar 27, 2026 |
| Mar 9, 2026 | Sale | Benjamin L Palleiko (CEO and Director) sold 6,693 shares at about $16.08 ($108K). Holdings down 1% to 451,815 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 10, 2026 |
| Feb 23, 2026 | Sale | Paul K. Audhya (Chief Medical Officer) sold 5,354 shares at about $15.57 ($83K). Holdings down 4% to 138,983 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 24, 2026 |
| Feb 23, 2026 | Sale | Nicole Sweeny (Chief Commercial Officer) sold 3,975 shares at about $15.57 ($62K). Holdings down 8% to 47,003 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 24, 2026 |
| Feb 23, 2026 | Sale | Brian Piekos (CFO) sold 1,767 shares at about $15.57 ($28K). Holdings down 11% to 13,762 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 24, 2026 |
| Feb 23, 2026 | Sale | Christopher Yea (Chief Development Officer) sold 4,347 shares at about $15.57 ($68K). Holdings down 2% to 226,701 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 24, 2026 |
| Feb 23, 2026 | Sale | Benjamin L Palleiko (CEO and Director) sold 10,034 shares at about $15.57 ($156K). Holdings down 2% to 442,883 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 24, 2026 |
| Feb 18, 2026 | Sale | Paul K. Audhya (Chief Medical Officer) sold 1,163 shares at $15.00 ($17K). Holdings down 1% to 133,087 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 19, 2026 |
| Feb 18, 2026 | Sale | Christopher Yea (Chief Development Officer) sold 1,109 shares at $15.00 ($17K). Holdings down <1% to 224,173 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 19, 2026 |
| Feb 18, 2026 | Sale | Benjamin L Palleiko (CEO and Director) sold 1,038 shares at $15.00 ($16K). Holdings down <1% to 429,667 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 19, 2026 |
| Feb 12, 2026 | Sale | Benjamin L Palleiko (CEO and Director) sold 3,354 shares at $15.70 ($53K). Holdings down 1% to 428,286 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 13, 2026 |
| Dec 8, 2025 | Sale | Benjamin L Palleiko (CEO and Director) sold 7,294 shares at $16.51 ($120K). Holdings down 2% to 424,520 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 9, 2025 |
| Nov 24, 2025 | Sale | Nicole Sweeny (Chief Commercial Officer) sold 3,813 shares at $13.45 ($51K). Holdings down 9% to 39,728 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 4, 2025 |
| Nov 24, 2025 | Sale | Paul K. Audhya (Chief Medical Officer) sold 5,296 shares at $13.45 ($71K). Holdings down 4% to 131,831 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 26, 2025 |
| Nov 24, 2025 | Sale | Brian Piekos (CFO) sold 4,471 shares at $13.45 ($60K). Holdings down 30% to 10,529 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 26, 2025 |
| Nov 24, 2025 | Sale | Christopher Yea (Chief Development Officer) sold 4,331 shares at $13.45 ($58K). Holdings down 2% to 223,508 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 26, 2025 |
| Nov 24, 2025 | Sale | Benjamin L Palleiko (CEO and Director) sold 10,940 shares at $13.45 ($147K). Holdings down 3% to 416,189 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 26, 2025 |
| Nov 18, 2025 | Sale | Paul K. Audhya (Chief Medical Officer) sold 3,075 shares at about $14.48 ($45K). Holdings down 2% to 125,877 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 19, 2025 |
| Nov 18, 2025 | Sale | Christopher Yea (Chief Development Officer) sold 2,683 shares at about $14.48 ($39K). Holdings down 2% to 133,574 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 19, 2025 |
| Nov 18, 2025 | Sale | Benjamin L Palleiko (CEO and Director) sold 4,466 shares at about $14.48 ($65K). Holdings down 1% to 403,879 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 19, 2025 |
| Nov 12, 2025 | Sale | Benjamin L Palleiko (CEO and Director) sold 3,328 shares at $11.55 ($38K). Holdings down 1% to 398,981 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 13, 2025 |
57 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow KALV in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.